189 related articles for article (PubMed ID: 37233702)
1. The Evaluation of
Giorgetti A; Amurri S; Fazio G; Bini C; Anniballi L; Pirani F; Pelletti G; Pelotti S
Metabolites; 2023 May; 13(5):. PubMed ID: 37233702
[TBL] [Abstract][Full Text] [Related]
2. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.
Aly SM; Hennart B; Gaulier JM; Allorge D
Toxics; 2024 Mar; 12(4):. PubMed ID: 38668482
[TBL] [Abstract][Full Text] [Related]
4. Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants.
Gloor Y; Lloret-Linares C; Bosilkovska M; Perroud N; Richard-Lepouriel H; Aubry JM; Daali Y; Desmeules JA; Besson M
Biomed Pharmacother; 2022 Aug; 152():113202. PubMed ID: 35653884
[TBL] [Abstract][Full Text] [Related]
5. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Drevin G; Picard N; Jousset N; Briet M; Abbara C
Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
[TBL] [Abstract][Full Text] [Related]
6. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.
Mostafa S; Polasek TM; Sheffield LJ; Huppert D; Kirkpatrick CMJ
Front Psychiatry; 2021; 12():724170. PubMed ID: 34489765
[No Abstract] [Full Text] [Related]
8. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
9. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.
Arici M; Özhan G
Saudi Pharm J; 2017 Mar; 25(3):376-380. PubMed ID: 28344492
[TBL] [Abstract][Full Text] [Related]
13. Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula.
Carano F; Sarno S; De Fanti S; Serventi P; Bini C; Luiselli D; Pelotti S
Ann Hum Biol; 2018 Feb; 45(1):66-71. PubMed ID: 28971704
[TBL] [Abstract][Full Text] [Related]
14. The impact of
de Jong LM; Boussallami S; Sánchez-López E; Giera M; Tushuizen ME; Hoekstra M; Hawinkels LJAC; Rissmann R; Swen JJ; Manson ML
Front Pharmacol; 2023; 14():1201906. PubMed ID: 37361233
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.
den Uil MG; Hut HW; Wagelaar KR; Abdullah-Koolmees H; Cahn W; Wilting I; Deneer VHM
Front Genet; 2023; 14():1249164. PubMed ID: 37693320
[No Abstract] [Full Text] [Related]
16. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
17. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
19. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases.
Jin SE; Seo CS; Shin HK; Ha H
Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
